CD274 and cancer: Siglec15 is upregulated in many human cancers, and as an immunosuppressive molecule that plays a role in the tumor microenvironment (TME), it is mutually exclusive with PD-L1 and has potential implications in patients with anti-PD-1/PD-L1 resistance (122, 123).